Swedish Orphan Biovitrum 관리

관리 기준 확인 4/4

Swedish Orphan Biovitrum CEO는 Guido Oelkers, May2017 에 임명되었습니다 의 임기는 7.58 년입니다. 총 연간 보상은 SEK 48.88M, 25.1% 로 구성됩니다. 25.1% 급여 및 74.9% 보너스(회사 주식 및 옵션 포함). 는 $ 11.98M 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 11.98M. 경영진과 이사회의 평균 재임 기간은 각각 5.9 년과 4.1 년입니다.

주요 정보

Guido Oelkers

최고 경영자

SEK 48.9m

총 보상

CEO 급여 비율	25.1%
CEO 임기	7.6yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	5.9yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Guido Oelkers 의 보수는 Swedish Orphan Biovitrum 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	SEK 4b
Jun 30 2024	n/a	n/a	SEK 2b
Mar 31 2024	n/a	n/a	SEK 2b
Dec 31 2023	SEK 49m	SEK 12m	SEK 2b
Sep 30 2023	n/a	n/a	SEK 3b
Jun 30 2023	n/a	n/a	SEK 3b
Mar 31 2023	n/a	n/a	SEK 3b
Dec 31 2022	SEK 47m	SEK 11m	SEK 3b
Sep 30 2022	n/a	n/a	SEK 2b
Jun 30 2022	n/a	n/a	SEK 3b
Mar 31 2022	n/a	n/a	SEK 3b
Dec 31 2021	SEK 42m	SEK 10m	SEK 3b
Sep 30 2021	n/a	n/a	SEK 3b
Jun 30 2021	n/a	n/a	SEK 3b
Mar 31 2021	n/a	n/a	SEK 3b
Dec 31 2020	SEK 33m	SEK 10m	SEK 3b
Sep 30 2020	n/a	n/a	SEK 3b
Jun 30 2020	n/a	n/a	SEK 3b
Mar 31 2020	n/a	n/a	SEK 4b
Dec 31 2019	SEK 33m	SEK 10m	SEK 3b
Sep 30 2019	n/a	n/a	SEK 3b
Jun 30 2019	n/a	n/a	SEK 3b
Mar 31 2019	n/a	n/a	SEK 3b
Dec 31 2018	SEK 26m	SEK 9m	SEK 2b
Sep 30 2018	n/a	n/a	SEK 2b
Jun 30 2018	n/a	n/a	SEK 2b
Mar 31 2018	n/a	n/a	SEK 1b
Dec 31 2017	SEK 16m	SEK 5m	SEK 1b

보상 대 시장: Guido 의 총 보상 ($USD 4.41M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 12.85M ).

보상과 수익: Guido 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Guido Oelkers (59 yo)

7.6yrs

테뉴어

SEK 48,883,000

보상

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

리더십 팀

이름	위치	테뉴어	보상	소유권
Guido Oelkers	CEO & President	7.6yrs	SEK 48.88m	0.12% $ 12.0m
Henrik Stenqvist	Chief Financial Officer	6.4yrs	데이터 없음	0.016% $ 1.6m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.9yrs	데이터 없음	0.0089% $ 855.3k
Daniel Rankin	Head of Strategy & Corporate Development	2.9yrs	데이터 없음	0.0029% $ 275.5k
Lena Bjurner	Head of Human Resources	1.9yrs	데이터 없음	데이터 없음
Armin Reininger	Senior Scientific & Medical Advisor	7.9yrs	데이터 없음	0.0047% $ 448.8k
Norbert Oppitz	Head of International	7.2yrs	데이터 없음	0.012% $ 1.1m
Sofiane Fahmy	Head of Europe	5.9yrs	데이터 없음	0.0077% $ 743.6k
Duane Barnes	Head of North America	3.9yrs	데이터 없음	데이터 없음
Mahmood Ladha	Head of Strategic Transformation Operations	no data	데이터 없음	0.0018% $ 175.3k
Christine Wesstrom	Head of Technical Operations	2.8yrs	데이터 없음	0.0032% $ 310.1k
Lydia Abad-Franch	Senior VP	1.9yrs	데이터 없음	데이터 없음

5.9yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: BIOV.F 의 관리팀은 노련하고 경험 (평균 재직 기간 5.9 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hans Wigzell	Chairman of Scientific Advisory Board	23.9yrs	SEK 158.00k	데이터 없음
Helena Saxon	Director	13.7yrs	SEK 828.00k	0.0067% $ 641.5k
Anders Ullman	Director	1.6yrs	SEK 463.00k	0.0010% $ 96.3k
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ralf Pettersson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Stefan Del Prato	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Annette Clancy	Independent Director	10.6yrs	SEK 770.00k	0.00099% $ 95.4k
Staffan Schuberg	Independent Director	4.6yrs	SEK 827.00k	0.0021% $ 200.3k
Filippa Stenberg	Director	3.6yrs	SEK 673.00k	0.00017% $ 16.4k
David Meek	Chairman	no data	데이터 없음	데이터 없음
Katy Mazibuko	Employee Representative Director	1.9yrs	데이터 없음	0.0013% $ 122.3k

4.1yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: BIOV.F 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/25 05:36
장 마감 주가	2024/12/23 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Swedish Orphan Biovitrum AB (publ) 29 애널리스트 중 11 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Alexander Lindström	ABG Sundal Collier
Rosie Turner	Barclays
Brian Balchin	Barclays

Swedish Orphan Biovitrum 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Recent updates

Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa

Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi

Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member

Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study

Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH)

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022

Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others.

Swedish Orphan Biovitrum AB (publ) Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia

Nature Medicine Publishes Phase 3 Anakinra Study Results in Patients with Covid-19 Pneumonia

Orphan Biovitrum Jumps After Bloomberg Report of Potential Takeover

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Swedish Orphan Biovitrum AB (publ) Announces Early Use of Anakinra Reduces Risk of Mortality for Patients with Covid-19 Pneumonia, Reduces ICU Admission and Increases Likelihood of Full Recovery

Swedish Orphan Biovitrum AB (Publ) and Hellenic Institute for the Study Announce Positive Top Line Results from the Investigator-Sponsored Save-More Study

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Full Year 2021

The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Swedish Orphan Biovitrum AB (publ) Announces First Patient Dosed with Avatrombopag

Swedish Orphan Biovitrum AB (publ) Announces Approval of Kineret® (anakinra) in Russia for the Treatment of CAPS

Swedish Orphan Biovitrum AB (publ) Announces Doptelet (avatrombopag) Approved in the EU for Treatment of ITP

Swedish Orphan Biovitrum AB (Publ) Appoints Duane Barnes as the New Head of Sobi in North America

Swedish Orphan Biovitrum's Doptelet® (Avatrombopag) Receives Positive Opinion from CHMP for Treatment of ITP

Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH

Sobi and Apellis Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan

Swedish Orphan Biovitrum AB (publ) Announces CHMP Adopts Negative Opinion for Emapalumab in Europe for the Treatment of Primary HLH

Sobi launch Doptelet® (avatrombopag) in Europe

Swedish Orphan Biovitrum AB (Publ) Announces Favorable Paediatric Data Results in Alprolix ® Product Information Update

Apellis, Enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications Outside the US

Sobi™ Presents Results from the Sensitivity Analysis from the Pivotal Phase 2/3 Study

Swedish Orphan Biovitrum AB (Publ) Announces Phase 3 Data of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia